Flagstar Bank NA vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: Flagstar Bank NA is far larger — about 2.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Flagstar Bank NA pays a 0.35% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| FLG | SLS | |
|---|---|---|
Market Cap | $4.71B | $2.27B |
Volume | 7,410,589 | 4,179,659 |
Sector | Financials | Health |
52-Week High | $15.36 | $15.46 |
52-Week Low | $10.72 | $1.39 |
Typical Hold Time | 21 Days | — |
Enterprise Value | $15.25B | $2.14B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.30, down 2.25% today, with a bearish technical signal despite bullish oscillators. The stock shows mixed fundamentals with a high P/E of 376.67 but trades below book value (P/B 0.61). Recent Q2 2026 earnings missed expectations, though the company reported its third consecutive profitable quarter. Analyst consensus remains strongly bullish with a $17.07 price target and no sell ratings.
The outlook suggests potential upside from current depressed levels, supported by analyst optimism and strategic initiatives like the $250M share repurchase program. Key risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. The stock presents a value opportunity but requires careful monitoring of execution on profitability targets.
No Aura AI signal available yet.
Trailing returns across standard periods
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →